Denali Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

DNLI$19.85-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2025	156,182,177	$1,888	$3,062,715	$682	$(2,051,524)	$1,013,761
Issuance of common stock, net of issuance cost of $45	746,468	8	12,358	—	—	12,366
Issuances under equity incentive plans	1,484,925	14	21,686	—	—	21,700
Vesting of restricted stock units	1,341,956	14	(14)	—	—	—
Stock-based compensation	—	—	46,002	—	—	46,002
Net loss	—	—	—	—	(256,000)	(256,000)
Other comprehensive loss	—	—	—	(2,651)	—	(2,651)
June 30, 2026	159,755,526	$1,924	$3,142,747	$(1,969)	$(2,307,524)	$835,178
Balance at March 31, 2026	158,656,318	$1,913	$3,104,838	$(682)	$(2,179,971)	$926,098
Issuances under equity incentive plans	948,205	9	14,996	—	—	15,005
Vesting of restricted stock units	151,003	2	(2)	—	—	—
Stock-based compensation	—	—	22,915	—	—	22,915
Net loss	—	—	—	—	(127,553)	(127,553)
Other comprehensive loss	—	—	—	(1,287)	—	(1,287)
June 30, 2026	159,755,526	$1,924	$3,142,747	$(1,969)	$(2,307,524)	$835,178
Balance at December 31, 2024	144,220,986	$1,768	$2,764,880	$2,020	$(1,538,984)	$1,229,684
Issuances under equity incentive plans	455,335	5	4,647	—	—	4,652
Vesting of restricted stock units	1,009,121	10	(10)	—	—	—
Stock-based compensation	—	—	50,887	—	—	50,887
Net loss	—	—	—	—	(257,089)	(257,089)
Other comprehensive loss	—	—	—	(1,081)	—	(1,081)
Balance at June 30, 2025	145,685,442	$1,783	$2,820,404	$939	$(1,796,073)	$1,027,053
Balance at March 31, 2025	145,251,258	$1,778	$2,790,825	$2,037	$(1,671,954)	$1,122,686
Issuances under equity incentive plans	341,543	4	4,053	—	—	4,057
Vesting of restricted stock units	92,641	1	(1)	—	—	—
Stock-based compensation	—	—	25,527	—	—	25,527
Net loss	—	—	—	—	(124,119)	(124,119)
Other comprehensive loss	—	—	—	(1,098)	—	(1,098)
Balance at June 30, 2025	145,685,442	$1,783	$2,820,404	$939	$(1,796,073)	$1,027,053

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.